Whitepaper
Predicting Physical Stability of Amorphous Solid Dispersions (ASD)
12 Feb 2026
en
Overcoming solubility challenges in BCS II & IV compounds through world-class Spray Drying and Hot-Melt Extrusion platforms.
Solubility challenges impact 70–90% of molecules in development. Crystal Pharmatech leverages this dual mechanism to dramatically enhance bioavailability:
Converts crystalline API to high-energy amorphous form for rapid supersaturation.
Polymer matrices inhibit recrystallization, sustaining the absorption window in vivo.
Our core team possesses a strong background in polymer science, chemistry, and engineering to support rapid, high-quality formulation development.
Have a question or need support with your project? Please complete the form, and our team will get back to you shortly.
Our capabilities span three specialized platforms:
Small Molecule
Crystal Bio Solutions
Crystal NAX
By providing your e-mail address, you agree to receive an e-mail response from Crystal Pharmatech to your inquiry. The information you submit will be governed by our Privacy Policy.
Subscribe to be the first to get the updates!